Preclinical Medication Development: New Targets and New Drugs
dc.contributor.author | Kasten, Chelsea R. | |
dc.contributor.author | Boehm, Stephen L., II | |
dc.contributor.department | Psychology, School of Science | en_US |
dc.date.accessioned | 2018-05-07T14:22:34Z | |
dc.date.available | 2018-05-07T14:22:34Z | |
dc.date.issued | 2016-07 | |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Kasten, C. R., & Boehm, S. L. (2016). Preclinical Medication Development: New Targets and New Drugs. Alcoholism, Clinical and Experimental Research, 40(7), 1418–1424. http://doi.org/10.1111/acer.13105 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/16077 | |
dc.language.iso | en_US | en_US |
dc.publisher | Wiley | en_US |
dc.relation.isversionof | 10.1111/acer.13105 | en_US |
dc.relation.journal | Alcoholism, Clinical and Experimental Research | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Neuropeptides | en_US |
dc.subject | Inflammation | en_US |
dc.subject | Neuroimmunology | en_US |
dc.subject | Alcoholism -- Complications | en_US |
dc.title | Preclinical Medication Development: New Targets and New Drugs | en_US |
dc.type | Article | en_US |